The Archive · 4 posts

Arecor Therapeutics PLC

Innovating treatments for a healthier future! 🧬 Arecor Therapeutics (AREC) is advancing health with cutting-edge therapeutic solutions. 💊

SubscribeRSS JSON

Arecor Therapeutics Reports 2025 Full-Year Results with Key Advances in Diabetes and Oral Peptide Delivery

Arecor's 2025 results showcase advances in diabetes with AT278 insulin nearing Phase 2 and oral peptide delivery progress, extending cash runway to 2027.

April 13, 2026

Browse All

Investing

Arecor Therapeutics Posts Interim Results with Key Partnerships and Extended Cash Runway

JoshuaSeptember 25, 2025

Investing

Arecor Partners with Skye Bioscience to Develop Enhanced Obesity Drug Nimacimab

Arecor & Skye Bioscience partner to develop nimacimab, an obesity drug with improved formulation & less frequent dosing via Arestat™ tech.

JoshuaMay 19, 2025

Investing

Arecor Therapeutics Positions for Growth with Diabetes Breakthrough and Oral Peptide Innovation

Arecor's diabetes breakthrough AT278 & oral peptide tech drive 2024 growth. Phase I success, partnerships & biopharma innovation.

JoshuaApril 22, 2025

Arecor Therapeutics PLC

Join the newsletter

Arecor Therapeutics Reports 2025 Full-Year Results with Key Advances in Diabetes and Oral Peptide Delivery

Browse All

Arecor Therapeutics Posts Interim Results with Key Partnerships and Extended Cash Runway

Arecor Partners with Skye Bioscience to Develop Enhanced Obesity Drug Nimacimab

Arecor Therapeutics Positions for Growth with Diabetes Breakthrough and Oral Peptide Innovation

Get the latest Investment news

Got an investment you want to share?

Arecor Therapeutics Positions for Growth with Diabetes Breakthrough and Oral Peptide Innovation